3 recruiting, 2 terminated. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Terminated 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow NF1 Mutation: new trials by email Literature Review of NF1 Mutation trials Research Report on NF1 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas PAS-004 Tablets, PAS-004 Capsule - NF1 Mutation, Neurofibroma Plexiform | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 56 | 2025-05-30 | 2026-10-28 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| PAS-004 in Patients With Advanced Solid Tumors PAS-004 Capsules, PAS-004 Tablets - RAS Mutation, NF1 Mutation | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 83 | 2024-02-29 | 2026-10-30 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies Fludarabine, Busulfan, Melphalan - Hematologic Malignancy, Acute Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 70 | 2023-05-11 | 2026-04-06 |
| Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. ABM-168 - Advanced Solid Tumor, RAS Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 12 | 2023-03-30 | 2024-12-06 |
Melanoma (2) · Neurofibromatosis 1 (2) · Anemia, Refractory, with Excess of Blasts (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Chromosome 7, monosomy (1) · Chromosome Aberrations (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Hematologic Neoplasms (1) · Influenza, Human (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Juvenile (1) · Lung Neoplasms (1) · Neoplasm, Residual (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Nerve Tissue (4) · Neoplasms by Site (3) · Nervous System Diseases (3) · Respiratory Tract Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Lung Diseases (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplastic Syndromes, Hereditary (2) · Nerve Sheath Neoplasms (2) · Nervous System Neoplasms (2) · Neurocutaneous Syndromes (2)
Busulfan (1) · Cyclophosphamide (1) · Levetiracetam (1) · Melphalan (1) · Rituximab (1) · fludarabine (1) · thymoglobulin (1)
Pasithea Therapeutics Corp. (2) · ABM Therapeutics Corporation (1) · Deciphera Pharmaceuticals, LLC (1) · Masonic Cancer Center, University of Minnesota (1)
United States (5) · Australia (1) · Bulgaria (1) · Romania (1) · South Korea (1)
Kartik Krishnan, MD, PhD (2) · Margaret MacMillan (1)